Clinicopathologic factors associated with the development of sunitinib-induced hypertension (HTN) in patients (pts) with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Neiman, Victoria
Gottfried, Maya
Hammers, Hans J.
Eisenberger, Mario A.
Carducci, Michael Anthony
Sinibaldi, Victoria J.
Rosenbaum, Eli
Sarid, David
Gez, Eliahu
Peer, Avivit
Neumann, Avivit
Kovel, Svetlana
Selia, Avishay
Mermershtain, Wilmesh
Rouvinov, Keren
Berger, Raanan
Keizman, Daniel
机构：
[1] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel
[2] Meir Med Ctr, Lung Canc Unit, Kefar Sava, Israel
[3] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[4] Rabin Med Ctr, Dept Oncol, Petah Tiqwa, Israel
[5] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Div Oncol, IL-69978 Tel Aviv, Israel
[6] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[7] Rambam Hlth Care Campus, Haifa, Israel
[8] Rambam Med Ctr, Dept Oncol, Haifa, Israel
[9] Asaf Harofe Med Ctr, Dept Oncol, Zerifin, Israel
[10] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel
[11] Soroka Med Ctr, Beer Sheva, Israel
[12] Meir Med Ctr, Dept Oncol, Kefar Sava, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e15551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15551
引用
收藏
页数：1
相关论文
共 50 条
  • [31] WBC changes as a pharmacodynamic marker of outcome in metastatic renal cell carcinoma (mRCC) patients (Pts) receiving sunitinib
    George, S.
    Richmond, A.
    Elson, P.
    Jin, T.
    Wood, L.
    Garcia, J. A.
    Rini, B. I.
    Finke, J.
    Bukowski, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Does Sunitinib-Induced Hypothyroidism Play a Role in the Activity of Sunitinib in Metastatic Renal Cell Carcinoma?
    Sella, Avishay
    Hercbergs, Aleck H.
    Hanovich, Ekaterina
    Kovel, Svetlana
    CHEMOTHERAPY, 2012, 58 (03) : 200 - 205
  • [33] Pharmacogenetic determinants of sunitinib-induced toxicity in Korean patients with metastatic renal cell carcinoma.
    Kim, H. R.
    Kwon, W. S.
    Youn, L. Gui
    Ahn, J. R.
    Park, H. J.
    Kim, H. S.
    Shin, S. J.
    Ahn, J. B.
    Rha, S. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] SAFETY PROFILE OF SUNITINIB AND SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Massari, Francesco
    Sperandi, Francesca
    Cricca, Antonia
    Melotti, Barbara
    Martoni, Andrea Angelo
    ANNALS OF ONCOLOGY, 2009, 20
  • [35] CARDIOTOXICITY IN METASTATIC RENAL CELL CARCINOMA (mRCC) PATIENTS TREATED WITH SUNITINIB (SU)
    Ballatore, Valentina
    Prati, Veronica
    Ruatta, Fiorella
    Galizia, Danilo
    Grignani, Giovanni
    Aglietta, Massimo
    Ortega, Cinzia
    ANTICANCER RESEARCH, 2012, 32 (05) : 1876 - 1877
  • [36] Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC).
    Houk, B. E.
    Amantea, M.
    Motzer, R. J.
    Michaelson, M. D.
    Rini, B. I.
    George, D. J.
    Redman, B. G.
    Hudes, G. R.
    Poland, B.
    Bello, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
  • [37] Sunitinib in patients with cytokine-refiractory metastatic renal cell carcinoma (mRCC)
    George, D. J.
    Michaelson, M. D.
    Rosenberg, J. E.
    Redman, B. G.
    Hudes, G. R.
    Bukowski, R. M.
    Kim, S. T.
    Chen, I.
    Wilding, G.
    Motzer, R. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 304 - 304
  • [38] Phase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Gordon, M. S.
    Stein, M.
    Shannon, P.
    Eddy, S.
    Tyler, A.
    Catlett, L.
    Hsyu, P.
    Huang, B.
    Healey, D.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Patel, P. H.
    Kondagunta, G. V.
    Redman, B. G.
    Hudes, G. R.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Outcome of octogenarian versus (vs) young patients (pts) with metastatic renal cell carcinoma (mRCC), treated with sunitinib (su).
    Kushnir, Igal
    Rosenbaum, Eli
    Sella, Avishay
    Sarid, David
    Gottfried, Maya
    Maimon, Natalie
    Peer, Avivit
    Neumann, Avivit
    Neiman, Victoria
    Kovel, Svetlana
    Gez, Eliahu
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Hammers, Hans J.
    Sinibaldi, Victoria J.
    Berger, Raanan
    Keizman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345